<!DOCTYPE html><html><head><meta charset='utf-8'><meta name='viewport' content='width=device-width, initial-scale=1'><script async src='https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-8422244967817077' crossorigin=anonymous'></script><link rel='stylesheet' href='/class.css'><script src='/script.js'></script></head><body><div class='topnav'></div><div class='list'><Br/><a href='4210.html'>4210</a><Br/><a href='4211.html'>4211</a><Br/><a href='4212.html'>4212</a><Br/><a href='4213.html'>4213</a><Br/><a href='4214.html'>4214</a><Br/><a href='4215.html'>4215</a><Br/><a href='4216.html'>4216</a><Br/><a href='4217.html'>4217</a><Br/><a href='4218.html'>4218</a><Br/><a href='4219.html'>4219</a></div><div class='stats'><div class='logodiv'><a href='/'><img class='logoimg' src='/img/elephant.svg' /></a></div> <Br/><a href='4208.html'>4208</a><Br/><a href='4207.html'>4207</a><Br/><a href='4206.html'>4206</a><Br/><a href='4205.html'>4205</a><Br/><a href='4204.html'>4204</a><Br/><a href='4203.html'>4203</a><Br/><a href='4202.html'>4202</a><Br/><a href='4201.html'>4201</a><Br/><a href='4200.html'>4200</a><Br/><a href='4199.html'>4199</a></div><div class='nav'><a href='4208.html'> << </a>&nbsp;&nbsp;&nbsp;&nbsp;<a href='4210.html'> >> </a></div><div class='article'>Dendritic cells and HIV-1 infection.
Dendritic cells (DC) are potent antigen presenting cells responsible for the activation of naive T cells and therefore are potential targets for HIV-1. In vitro studies have demonstrated that DC are rapidly and efficiently infected with HIV-1. Productive infection is mediated in part by chemokine receptors that function as coreceptors. The infection leads to loss of DC maturation, alteration of DC morphology, downregulation of MHC class I and class II molecules, and the production of interferon gamma (IFN-gamma). Viral proteins produced as a result of HIV-1 replication affect DC function, leading to apoptosis and altered cytokine secretion. These alterations can be reversed by IL-12, which can be supplied by a novel DC-based vaccine (DC/SFU), where the vaccine is made up of autologous, interleukin-2 (IL-2) expanded T cells and a recombinant vaccinia expressing IL-12. This vaccine is also able to inhibit viral replication and downmodulate viral transcription. This vaccine reverses the effects of HIV-1 infection on DC and stimulates autologous T cells to proliferate and produce IFN-gamma, thereby producing a DC-induced immune response. Further studies are underway to determine whether this vaccination regimen can prevent HIV-1 infection in humans.</div></body></html><!-- 2022-06-25 08:33:10 